Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedJun 11, 2026
DataAggregated Company Financials
Companies1402
  • 7D2.8%
  • 3M3.5%
  • 1Y13.9%
  • YTD-2.0%

The Healthcare industry is up 2.8% in the last week, with Eli Lilly up 5.3%. In the same time, Gilead Sciences was down 5.8%. This takes the industry's 12 month performance to a gain of 14%. Looking forward, earnings are forecast to grow by 18% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 12 Jun 2026US$6.5tUS$3.3tUS$122.2b22.7x53.3x2x
Sun, 10 May 2026US$6.2tUS$3.3tUS$123.8b22.9x50.2x1.9x
Tue, 07 Apr 2026US$6.2tUS$3.3tUS$127.9b22.5x48.5x1.9x
Thu, 05 Mar 2026US$6.5tUS$3.3tUS$126.3b25.6x51.5x2x
Sat, 31 Jan 2026US$6.5tUS$3.2tUS$126.6b27.8x51.1x2x
Mon, 29 Dec 2025US$6.6tUS$3.2tUS$135.2b26.5x48.5x2.1x
Wed, 26 Nov 2025US$6.4tUS$3.2tUS$133.6b26.7x48.3x2x
Fri, 24 Oct 2025US$6.1tUS$3.1tUS$140.8b25.5x43.1x2x
Sun, 21 Sep 2025US$5.7tUS$3.1tUS$137.6b23.9x41.4x1.8x
Tue, 19 Aug 2025US$5.7tUS$3.1tUS$136.9b23x41.3x1.8x
Thu, 17 Jul 2025US$5.4tUS$3.0tUS$127.9b23.3x42.6x1.8x
Sat, 14 Jun 2025US$5.6tUS$3.0tUS$127.4b23.5x43.8x1.8x
Mon, 12 May 2025US$5.4tUS$3.0tUS$126.6b24.2x42.4x1.8x
Wed, 09 Apr 2025US$5.2tUS$2.6tUS$81.6b24.1x63.6x2x
Fri, 07 Mar 2025US$5.9tUS$2.6tUS$79.1b27x74.2x2.2x
Sun, 02 Feb 2025US$6.1tUS$2.9tUS$85.1b27.8x72x2.1x
Tue, 31 Dec 2024US$5.8tUS$2.9tUS$79.3b27.5x73.4x2x
Thu, 28 Nov 2024US$6.1tUS$2.9tUS$77.1b28.5x79.4x2.1x
Sat, 26 Oct 2024US$6.1tUS$2.9tUS$59.1b29.1x102.6x2.1x
Mon, 23 Sep 2024US$6.3tUS$2.8tUS$60.1b30.1x104.6x2.2x
Wed, 21 Aug 2024US$6.2tUS$2.8tUS$55.9b31.9x110.8x2.2x
Fri, 19 Jul 2024US$6.4tUS$2.8tUS$60.8b31.3x105.5x2.3x
Sun, 16 Jun 2024US$6.2tUS$2.8tUS$62.4b29.9x99.1x2.2x
Tue, 14 May 2024US$6.1tUS$2.8tUS$63.9b30.6x95.7x2.2x
Thu, 11 Apr 2024US$6.2tUS$2.8tUS$85.2b32.1x72.4x2.2x
Sat, 09 Mar 2024US$6.3tUS$2.8tUS$82.9b32.5x75.9x2.3x
Mon, 05 Feb 2024US$6.4tUS$2.8tUS$76.4b31.9x84.1x2.3x
Wed, 03 Jan 2024US$6.3tUS$2.8tUS$90.3b32.5x69.9x2.2x
Fri, 01 Dec 2023US$5.8tUS$2.8tUS$91.4b28.4x63.8x2.1x
Sun, 29 Oct 2023US$5.5tUS$2.8tUS$99.5b24.1x55.6x2x
Tue, 26 Sep 2023US$5.9tUS$2.8tUS$98.5b27.9x60.2x2.1x
Thu, 24 Aug 2023US$6.1tUS$2.8tUS$99.0b28.4x61.8x2.2x
Sat, 22 Jul 2023US$6.2tUS$2.7tUS$110.9b26.9x55.5x2.2x
Mon, 19 Jun 2023US$6.0tUS$2.7tUS$109.9b26.4x54.8x2.2x
Price to Earnings Ratio

54.8x


Total Market Cap: US$6.0tTotal Earnings: US$109.9bTotal Revenue: US$2.7tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 53.3x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 3.6% per year over the last three years.
  • Revenues for these companies have grown 6.9% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market-4.05%
Healthcare2.77%
Healthcare Services6.61%
Pharma4.51%
Medical Equipment2.75%
Life Sciences0.57%
Biotech-1.89%
Healthtech-5.69%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 54.0x.
    • Analysts expect its future annual earnings growth (16.2%) to be largely in line with prior year's earnings growth.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 25% over the next 5 years.
  • However this is lower than its past earnings growth rate of 55% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 15% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$1.16k3.2%
+US$31.8b		43.0%PE41x
JNJ Johnson & JohnsonUS$238.334.5%
+US$24.5b		52.1%PE27.3x
UNH UnitedHealth GroupUS$405.552.3%
+US$8.2b		27.3%PE30.6x
CVS CVS HealthUS$100.486.0%
+US$7.2b		51.4%PE43.7x
AMGN AmgenUS$354.062.4%
+US$4.6b		19.1%PE24.5x

Latest News

JNJ
US$238.33
Johnson & Johnson
7D
4.5%
1Y
52.1%
ONC
US$260.27
BeOne Medicines
7D
-7.0%
1Y
-5.9%
DHR
US$180.79
Danaher
7D
-3.1%
1Y
-11.9%
LLY
US$1,160.95
Eli Lilly
7D
3.2%
1Y
43.0%
CVS
US$100.48
CVS Health
7D
6.0%
1Y
51.4%
BSX
US$47.17
Boston Scientific
7D
-3.4%
1Y
-52.1%
AMGN
US$354.06
Amgen
7D
2.4%
1Y
19.1%
GILD
US$125.87
Gilead Sciences
7D
-2.6%
1Y
12.3%
TMO
US$475.66
Thermo Fisher Scientific
7D
-1.3%
1Y
14.5%
Narrative Update • Jun 09

TMO: AI Tools And Proteomics Platforms Will Drive Future Upside

Thermo Fisher Scientific's updated fair value estimate has moved down from about $738 to $721 per share as analysts temper longer term revenue growth assumptions, partly reflecting recent price target cuts and more cautious views on organic growth momentum, even as they acknowledge that the company's margin profile and P/E remain supportive. Analyst Commentary Recent Street research paints a mixed picture for Thermo Fisher Scientific, with some analysts turning more cautious on near term organic growth while others highlight the stock as a core holding for exposure to life science tools.
HCA
US$378.51
HCA Healthcare
7D
4.6%
1Y
1.8%
New Narrative • Jun 09

Capital Investment And Outpatient Expansion Will Reshape Long Term Performance

Catalysts About HCA Healthcare HCA Healthcare operates a large network of hospitals and outpatient facilities that provide acute care, emergency services and a wide range of specialty care across multiple US markets. What are the underlying business or industry changes driving this perspective?
ELV
US$399.18
Elevance Health
7D
-2.5%
1Y
3.4%
CAH
US$221.16
Cardinal Health
7D
9.6%
1Y
37.8%
A
US$129.55
Agilent Technologies
7D
-6.4%
1Y
8.9%
Narrative Update • Jun 06

A: AI Partnerships And New Diagnostics Offer Compelling Future Upside Potential

Analysts have adjusted their price target on Agilent Technologies slightly to $161.00. This reflects updated assumptions around discount rate, long term revenue growth, profit margins and future P/E expectations.
UNH
US$405.55
UnitedHealth Group
7D
2.3%
1Y
27.3%
VEEV
US$161.55
Veeva Systems
7D
-9.5%
1Y
-42.7%
CI
US$294.84
Cigna Group
7D
5.0%
1Y
-6.5%
Narrative Update • Jun 01

CI: Portfolio Reshaping And CEO Transition Will Support Future Share Upside

Analysts have nudged their price target for Cigna Group slightly higher to about $341.50, reflecting updated assumptions for revenue, profit margins and a modestly higher future P/E multiple. What's in the News Cigna reported Q1 2026 adjusted EPS of US$7.79 on revenue of US$68.5b, above analyst expectations, and raised full year adjusted EPS guidance to at least US$30.35 per share, according to recent earnings coverage.